EQL Pharma ABOSTO:EQL +3.02%42 PS Ratio is 1.65 as of Jul. 06, 2026, which is 71% below its 10-year median of 5.69. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, EQL Pharma AB ranks better than 61.76% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, EQL Pharma AB's share price is kr23.85.
EQL Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr14.42. Hence, EQL Pharma AB's PS Ratio for today is 1.65.
Good Sign:
EQL Pharma AB stock PS Ratio (=1.66) is close to 2-year low of 1.64.
The historical rank and industry rank for EQL Pharma AB's PS Ratio or its related term are showing as below:
OSTO:EQL'
s PS Ratio Range Over the Past 10 Years
Min: 1.64 Med: 5.69 Max: 7.75
Current: 1.65
During the past 13 years, EQL Pharma AB's highest PS Ratio was 7.75. The lowest was 1.64. And the median was 5.69.
OSTO:EQL's PS Ratio is ranked better than 61.76% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs OSTO:EQL: 1.65
EQL Pharma AB has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of EQL Pharma AB was 14.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 17.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 35.00% per year.
During the past 13 years, EQL Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 100.80% per year. The lowest was -12.10% per year. And the median was 17.70% per year.
Back to Basics: PS Ratio
EQL Pharma AB (OSTO:EQL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
EQL Pharma AB PS Ratio Related Terms
EQL Pharma AB PS Ratio Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
EQL Pharma AB's Share Price of today is kr23.85. EQL Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr14.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
EQL Pharma AB (OSTO:EQL) has a PS Ratio of 1.65 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on EQL Pharma AB and its competitors. This is 71% below median its historical median of 5.69. Over the past decade, EQL Pharma AB's PS Ratio has ranged from 1.64 to 7.75. According to the industry distribution chart, EQL Pharma AB ranks #364 out of 952 companies in the Drug Manufacturers industry, placing it in the top 38.2%.
Is EQL Pharma AB's PS Ratio too high?
EQL Pharma AB's current PS Ratio of 1.65 is 71% below median its 10-year median of 5.69. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 7.75. The Drug Manufacturers industry median PS Ratio is 2.32. EQL Pharma AB's value of 1.65 is 28.7% below this industry median. Based on the distribution chart, EQL Pharma AB ranks #364 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #364 out of 952 companies for PS Ratio. This puts EQL Pharma AB in the upper half of its industry. The industry median PS Ratio is 2.32. EQL Pharma AB's value of 1.65 is 28.7% below this benchmark. Historically, EQL Pharma AB's own PS Ratio has ranged from 1.64 to 7.75 over the past decade. While the company's 10-year median is 5.69 vs. the industry median of 2.32, EQL Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current PS Ratio of 1.65 is 28.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current PS Ratio is 1.65, which is 71% below median its own 10-year median of 5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current PS Ratio of 1.65. The current PS Ratio is 1.65, which is 71% below median its 10-year median of 5.69 and 28.7% below the Drug Manufacturers industry median of 2.32. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current PS Ratio is 1.65 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
